LEO Pharma introduces new Taclonex website for plaque psoriasis treatment

LEO Pharma Inc., a wholly-owned US subsidiary of LEO Pharma A/S, makers of Taclonex® brand products, today announced the launch of an enhanced and expanded website at www.taclonex.com. The website offers the most comprehensive information available regarding Taclonex® (calcipotriene 0.005% and betamethasone dipropionate 0.064%) Ointment and Taclonex Scalp® (calcipotriene 0.005% and betamethasone dipropionate 0.064%) Topical Suspension.

"Increasing numbers of patients turn to the web for information about psoriasis and available treatments," noted John Koconis, president and chief executive officer at LEO Pharma Inc. "We have enhanced the site so that patients can more easily discover information about Taclonex® brand products, the only once-daily prescription combination therapies for plaque psoriasis on the market."

Updates to the site include the addition of product information for both Taclonex® Ointment and Taclonex Scalp® and enhanced usability and navigation. Eligible patients can also download a personalized patient savings card for Taclonex® Ointment and/or Taclonex Scalp® prescriptions.

Psoriasis is a non-contagious, chronic disease of the immune system that affects an estimated 125 million people worldwide. According to the National Institutes of Health, more than seven million adult Americans have been diagnosed with psoriasis, of which 80% have plaque psoriasis. Plaque psoriasis generally appears as patches of raised, red skin covered by flaky white buildup of dead skin cells. These patches most often appear on the scalp, knees, elbows and torso, are often itchy and painful, and can crack and bleed.

Source: LEO Pharma Inc.